Seponering på grund af akut infusionsrelateret reaktion forekom hos 0, 4% af de abataceptbehandlede patienter og hos 0, 2% af de placebobehandlede.
Discontinuation due to an acute infusion-related reaction occurred in 0.4% of patients receiving abatacept and in 0.2% of placebo-treated patients.